Highest-materiality recent filing
Edwards shareholders approve 7M share increase in Long-Term Stock Program
Stockholders authorized 7M additional shares, raising total available to 341.5M under the amended program.
Edwards Lifesciences appoints Theodora Mistras as CFO, effective May 29, 2026
Theodora Mistras appointed CFO effective May 29, 2026, succeeding Scott Ullem (announced October transition).
Edwards Q1 sales +16.7% to $1.65B; raises FY guidance on TAVR strength
Q1 sales $1.65B, +16.7% YoY; constant currency +12.7%; TAVR sales $1.20B, +14.4%.
Edwards Q4 sales $1.57B (+13.3%), TAVR +12%, TMTT >40% growth; FY2026 guidance raised
Q4 GAAP EPS $0.11, adjusted EPS $0.58; gross margin 78.1% (78.3% adjusted).
US District Court grants FTC motion for injunction blocking Edwards' acquisition of JenaValve; deal terminated.
Edwards Q3 sales rise 14.7% to $1.55B; raises FY EPS guidance to $2.56-$2.62
Q3 sales $1.55B (+14.7% YoY); adjusted EPS $0.67 vs $0.50 GAAP.
Edwards Lifesciences CFO Scott Ullem to step down by mid-2026; successor search underway
CFO Scott Ullem informed company on Oct. 30, 2025 of decision to transition by mid-2026.
Edwards Lifesciences announces $500M accelerated share repurchase, initial ~5M shares
$500M accelerated share repurchase executed; initial delivery of ~5 million shares.
FTC moved to block Edwards' proposed acquisition of JenaValve Technology; Edwards disagrees and will continue pursuing regulatory approval.
Edwards Lifesciences EVP Larry Wood to resign; Daniel Lippis to lead TAVR business
Larry Wood, Corporate VP and Group President of TAVR and Surgical Structural Heart, resigns effective Sept 1, 2025.
Edwards Q2 sales up 11.9% to $1.53B; raises full-year guidance
Q2 GAAP EPS $0.57; adjusted EPS $0.67.
Edwards shareholders approve 5.66M new shares for employee stock purchase plans
Shareholders approved US ESPP amendment adding 4.2M shares and International ESPP adding 1.46M shares.
Edwards Q1 sales $1.41B (+6.2%), TMTT surging 58%, guidance raised
Q1 sales $1.41B (+6.2% reported, +7.9% adjusted); GAAP EPS $0.62, adjusted EPS $0.64.
Edwards Q4 sales $1.39B (+9%), adjusted EPS $0.59; reiterates 2025 guidance
Q4 sales $1.39B (+9% YoY); TAVR $1.04B (+6%), TMTT $105M (+88%).
Edwards Q3 sales up 9% to $1.33B; TAVR +6%, TMTT +73%; adjusted EPS $0.67 beats guidance
Q3 sales from continuing ops $1.33B (+9% as-reported, +10% constant currency); adjusted EPS $0.67 ahead of July guidance.
Edwards completes $4.2B sale of Critical Care to BD, adds $1.5B buyback
Closed all-cash sale of Critical Care to BD (NYSE: BDX) for $4.2B.
Edwards Q2 revenue +8% CC, TAVR guidance cut to 5-7%; announces $1.2B in acquisitions
Q2 continuing ops sales $1.35B (+7% reported, +8% CC); adj. EPS $0.70, GAAP EPS $0.61.
Edwards Lifesciences exercises option to acquire Innovalve for ~$300M cash
Edwards Lifesciences (EW) acquires early-stage TMVR company Innovalve Bio Medical Ltd.
Edwards Lifesciences appoints David T. Feinberg to Board, effective July 10
David T. Feinberg, M.D. appointed to Edwards Lifesciences Board and Audit Committee, effective July 10, 2024.
Robert W.A. Sellers, Senior VP and Principal Accounting Officer, retires effective July 1, 2024.
Edwards Lifesciences sells Critical Care unit to BD for $4.2B cash, ends spin-off
All-cash sale of Critical Care product group to BD (NYSE: BDX) valued at $4.2 billion.
Edwards Lifesciences annual meeting results: all four proposals approved by stockholders
All eight director nominees elected with >447M 'for' votes each.
Edwards Q1 sales $1.6B (+10%), TMTT +75%; raises FY sales guidance to high end 8-10%
Q1 sales $1.6B, up 10% reported and constant currency; GAAP EPS $0.58, adjusted EPS $0.66.
On May 4, 2026, Edwards Lifesciences Corporation, a Delaware corporation (the “Company”), announced that Theodora Mistras has been appointed as the Corporate Vice President, Chief Financial Officer of the Company, effective May 29, 2026, to succeed Scott B. Ullem in that position.
On July 10, 2024, Edwards Lifesciences Corporation, a Delaware corporation (the “Company”), appointed David T. Feinberg, M.D. to the Company’s Board of Directors (the “Board”), effective immediately.
Robert W.A. Sellers, Senior Vice President, Principal Accounting Officer of the Company, of his decision to retire, effective as of July 1, 2024
On the Retirement Date, Mr. Sellers will be succeeded by Andrew M. Dahl, currently Senior Vice President and Corporate Controller of the Company.
Max materiality 0.85 · Median 0.75 · Most common event earnings